Passive immunotherapy in neonatal calves-II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves

Sheikh A. Selim, Charles A. Holmberg, James S Cullor

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hyperimmunized bovine plasma containing antibodies to a mutant Escherichia coli O111:B4 (J5) was used to conduct a prospective double-blind clinical trial to evaluate its efficacy as an immunotherapy to bovine neonates in field conditions. Two- to three-day-old calves (N=150) were randomized into three groups (n=50) to receive (1) no plasma (NP) or (2) control (traces or no J5 antibody) bovine plasma (CP), or (3) hyperimmune bovine anti J5 plasma (HP) in two subcutaneous total doses of 10 ml kg-1 body weight at a 24 h interval. Various physiological, pathological and clinical parameters of the study subjects were observed up to three weeks while other data such as morbidity, mortality and the effect on heart girth increase were collected up to the end of the eighth week. Weekly serum total protein and immunoglobulin G (IgG) concentrations were preferentially increased from the baseline values in HP calves but not statistically significant (p>0.05) in group comparison. Mean (geometric) serum J5 ELISA titers in the HP group were significantly (p<0.001) higher than the other two groups that increased about 1-log by the first week of plasma intervention, followed by a gradual decline by the third week. Out of three total deaths due to septicemia and colitis, one was from the NP group while the other two were from the HP group. Morbidity as measured daily on a 13-point scoring scale were not statistically (p>0.05) different among the groups. Variation in the mean heart-girth increase was non-significant (p>0.05) among groups by the eighth week. Higher increase in heart girth was generally associated with higher initial serum IgG (p<0.01) concentration. Our results suggest that this lot of hyperimmune J5 plasma at this dose was not superior to control plasma or to no intervention in terms of calf morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)1454-1459
Number of pages6
JournalVaccine
Volume13
Issue number15
DOIs
StatePublished - 1995

Fingerprint

Passive Immunization
immunotherapy
Immunotherapy
girth
calves
Escherichia coli
cattle
heart
immunoglobulin G
morbidity
antibodies
dosage
Immunoglobulin G
normal values
blood proteins
Morbidity
clinical trials
neonates
Mortality
Antibodies

Keywords

  • E. coli J5
  • efficacy
  • hyperimmune plasma
  • immunotherapy
  • neonatal calves

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Immunology
  • Microbiology
  • Virology

Cite this

Passive immunotherapy in neonatal calves-II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves. / Selim, Sheikh A.; Holmberg, Charles A.; Cullor, James S.

In: Vaccine, Vol. 13, No. 15, 1995, p. 1454-1459.

Research output: Contribution to journalArticle

@article{02a9a1b472db4d21b50dca7ab1611ba6,
title = "Passive immunotherapy in neonatal calves-II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves",
abstract = "Hyperimmunized bovine plasma containing antibodies to a mutant Escherichia coli O111:B4 (J5) was used to conduct a prospective double-blind clinical trial to evaluate its efficacy as an immunotherapy to bovine neonates in field conditions. Two- to three-day-old calves (N=150) were randomized into three groups (n=50) to receive (1) no plasma (NP) or (2) control (traces or no J5 antibody) bovine plasma (CP), or (3) hyperimmune bovine anti J5 plasma (HP) in two subcutaneous total doses of 10 ml kg-1 body weight at a 24 h interval. Various physiological, pathological and clinical parameters of the study subjects were observed up to three weeks while other data such as morbidity, mortality and the effect on heart girth increase were collected up to the end of the eighth week. Weekly serum total protein and immunoglobulin G (IgG) concentrations were preferentially increased from the baseline values in HP calves but not statistically significant (p>0.05) in group comparison. Mean (geometric) serum J5 ELISA titers in the HP group were significantly (p<0.001) higher than the other two groups that increased about 1-log by the first week of plasma intervention, followed by a gradual decline by the third week. Out of three total deaths due to septicemia and colitis, one was from the NP group while the other two were from the HP group. Morbidity as measured daily on a 13-point scoring scale were not statistically (p>0.05) different among the groups. Variation in the mean heart-girth increase was non-significant (p>0.05) among groups by the eighth week. Higher increase in heart girth was generally associated with higher initial serum IgG (p<0.01) concentration. Our results suggest that this lot of hyperimmune J5 plasma at this dose was not superior to control plasma or to no intervention in terms of calf morbidity and mortality.",
keywords = "E. coli J5, efficacy, hyperimmune plasma, immunotherapy, neonatal calves",
author = "Selim, {Sheikh A.} and Holmberg, {Charles A.} and Cullor, {James S}",
year = "1995",
doi = "10.1016/0264-410X(95)00067-B",
language = "English (US)",
volume = "13",
pages = "1454--1459",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

TY - JOUR

T1 - Passive immunotherapy in neonatal calves-II. The efficacy of a J5 Escherichia coli hyperimmune plasma as immunotherapy in neonatal calves

AU - Selim, Sheikh A.

AU - Holmberg, Charles A.

AU - Cullor, James S

PY - 1995

Y1 - 1995

N2 - Hyperimmunized bovine plasma containing antibodies to a mutant Escherichia coli O111:B4 (J5) was used to conduct a prospective double-blind clinical trial to evaluate its efficacy as an immunotherapy to bovine neonates in field conditions. Two- to three-day-old calves (N=150) were randomized into three groups (n=50) to receive (1) no plasma (NP) or (2) control (traces or no J5 antibody) bovine plasma (CP), or (3) hyperimmune bovine anti J5 plasma (HP) in two subcutaneous total doses of 10 ml kg-1 body weight at a 24 h interval. Various physiological, pathological and clinical parameters of the study subjects were observed up to three weeks while other data such as morbidity, mortality and the effect on heart girth increase were collected up to the end of the eighth week. Weekly serum total protein and immunoglobulin G (IgG) concentrations were preferentially increased from the baseline values in HP calves but not statistically significant (p>0.05) in group comparison. Mean (geometric) serum J5 ELISA titers in the HP group were significantly (p<0.001) higher than the other two groups that increased about 1-log by the first week of plasma intervention, followed by a gradual decline by the third week. Out of three total deaths due to septicemia and colitis, one was from the NP group while the other two were from the HP group. Morbidity as measured daily on a 13-point scoring scale were not statistically (p>0.05) different among the groups. Variation in the mean heart-girth increase was non-significant (p>0.05) among groups by the eighth week. Higher increase in heart girth was generally associated with higher initial serum IgG (p<0.01) concentration. Our results suggest that this lot of hyperimmune J5 plasma at this dose was not superior to control plasma or to no intervention in terms of calf morbidity and mortality.

AB - Hyperimmunized bovine plasma containing antibodies to a mutant Escherichia coli O111:B4 (J5) was used to conduct a prospective double-blind clinical trial to evaluate its efficacy as an immunotherapy to bovine neonates in field conditions. Two- to three-day-old calves (N=150) were randomized into three groups (n=50) to receive (1) no plasma (NP) or (2) control (traces or no J5 antibody) bovine plasma (CP), or (3) hyperimmune bovine anti J5 plasma (HP) in two subcutaneous total doses of 10 ml kg-1 body weight at a 24 h interval. Various physiological, pathological and clinical parameters of the study subjects were observed up to three weeks while other data such as morbidity, mortality and the effect on heart girth increase were collected up to the end of the eighth week. Weekly serum total protein and immunoglobulin G (IgG) concentrations were preferentially increased from the baseline values in HP calves but not statistically significant (p>0.05) in group comparison. Mean (geometric) serum J5 ELISA titers in the HP group were significantly (p<0.001) higher than the other two groups that increased about 1-log by the first week of plasma intervention, followed by a gradual decline by the third week. Out of three total deaths due to septicemia and colitis, one was from the NP group while the other two were from the HP group. Morbidity as measured daily on a 13-point scoring scale were not statistically (p>0.05) different among the groups. Variation in the mean heart-girth increase was non-significant (p>0.05) among groups by the eighth week. Higher increase in heart girth was generally associated with higher initial serum IgG (p<0.01) concentration. Our results suggest that this lot of hyperimmune J5 plasma at this dose was not superior to control plasma or to no intervention in terms of calf morbidity and mortality.

KW - E. coli J5

KW - efficacy

KW - hyperimmune plasma

KW - immunotherapy

KW - neonatal calves

UR - http://www.scopus.com/inward/record.url?scp=0028825895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028825895&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)00067-B

DO - 10.1016/0264-410X(95)00067-B

M3 - Article

VL - 13

SP - 1454

EP - 1459

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -